Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research Medical autologous fibrinogen sealant to enter clinicals for hemostasis.

This article was originally published in The Gray Sheet

Executive Summary

RESEARCH MEDICAL'S AUTOLOGOUS FIBRINOGEN DELIVERY KIT U.S. CLINICALS, which are slated to begin this month at the University of New York at Stony Brook, will evaluate use of the AFD kit as a means of achieving topical hemostasis for the treatment of excessive bleeding from the donor skin site of burn patients. The company received an FDA investigational device exemption in April for the feasibility study, which will involve 12 to 15 subjects.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts